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ABSTRACT
Krabbe disease (KD) is an autosomal recessive neurodegenerative disorder 
caused by defective β-galactosylceramidase (GALC), a lysosomal enzyme responsible 
for cleavage of several key substrates including psychosine. Accumulation of 
psychosine to the cytotoxic levels in KD patients is thought to cause dysfunctions 
in myelinating glial cells based on a comprehensive study of demyelination in KD. 
However, recent evidence suggests myelin-independent neuronal death in the 
murine model of KD, thus indicating defective GALC in neurons as an autonomous 
mechanism for neuronal cell death in KD. These observations prompted us to generate 
induced neurons (iNeurons) from two adult-onset KD patients carrying compound 
heterozygous mutations (p.[K563*];[L634S]) and (p.[N228_S232delinsTP];[G286D]) 
to determine the direct contribution of autonomous neuronal toxicity to KD. Here 
we report that directly converted KD iNeurons showed not only diminished GALC 
activity and increased psychosine levels, as expected, but also neurite fragmentation 
and abnormal neuritic branching. The lysosomal-associated membrane proteins 1 
(LAMP1) was expressed at higher levels than controls, LAMP1-positive vesicles 
were significantly enlarged and fragmented, and mitochondrial morphology and its 
function were altered in KD iNeurons. Strikingly, we demonstrated that psychosine 
was sufficient to induce neurite defects, mitochondrial fragmentation, and lysosomal 
alterations in iNeurons derived in healthy individuals, thus establishing the causal 
effect of the cytotoxic GALC substrate in KD and the autonomous neuronal toxicity 
in KD pathology.
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INTRODUCTION
Krabbe disease (KD) characterized by globoid 
cell leukodystrophy is an autosomal recessive 
lysosomal storage disease caused by mutations in the 
β-galactosylceramidase (GALC) gene that impair the 
enzymatic function. While frequently detected in infants, 
KD has also been found as an adult-onset disease [1, 2]. 
Compared to rapid clinical progression in infants, adult-
onset KD patients show less severe phenotype with slower 
disease progression [2]. In most enzymatic lysosomal 
diseases, deficiencies in lysosomal enzyme activities are 
correlated with the degree of clinical severity. However, 
such relationship appears obscure with KD patients [3, 
4]. This discrepancy between loss of enzymatic activity 
and disease phenotype has made it difficult to predict 
the phenotype of GALC mutations, which are often 
heterozygous in KD patients.
During myelin turnover, GALC catabolizes 
the primary substrate galactosylceramide (GalCer) to 
galactose and ceramide, and the secondary substrate 
psychosine to galactose and sphingosine [5]. Both GalCer 
and psychosine are processed in the lysosome and their 
recycled components have been found to enter the 
remyelination pathway in the nervous system [6]. This 
leads to the proposal that compromised GALC enzymatic 
activity in KD results in insufficient degradation of 
both GalCer and psychosine, thus causing reduced 
remyelination efficiency in the nervous system [1]. 
While impaired remyelination has been thought 
to be a direct cause of axonal dystrophy in KD, recent 
evidence suggests that myelin loss appears to be 
insufficient to count for defects in neurons and axons 
in the Twitcher mouse model, because cultured neurons 
from the Twitcher mice exhibit typical neuronal and 
axonal defects in the absence of disrupted myelinating 
glia, thus indicating autonomous neuronal damage in 
KD [7-9]. Moreover, psychosine has also been found to 
alter the angiogenesis process in the murine model, and 
linked to neuronal inclusion of misfolded and aggregated 
ɑ-synuclein in postmortem brains from both infantile and 
late onset KD patients [10, 11]. These studies all point to 
potential autonomous neuronal dysfunction independent of 
myelin defects in leukodystrophic pathology, which may 
in fact precede myelin loss. However, our understanding 
of the pathogenic role of myelin-independent neuronal 
degeneration in KD has been hampered by the lack of 
patient-derived cellular models that are able to recapitulate 
human KD pathologies.
In the present study, we generated and characterized 
induced neurons (iNeurons) derived from two adult-onset 
KD patients carrying GALC (p.[K563*];[L634S]) and 
(p.[N228_S232delinsTP];[G286D]). Using these disease-
relevant and the patient-specific cell models, we report 
abnormal GALC enzymatic activities and psychosine 
levels in patient cells. In patient-derived iNeurons, we 
demonstrate a direct relationship of GALC mutation 
and abnormal psychosine accumulation with axonal 
and dendritic defects with morphological and functional 
impairments in lysosomes and mitochondria. These 
myelin-independent axonal and neuronal defects thus 
strongly argue for autonomous neuronal toxicity in adult-
onset KD.
RESULTS
Clinical manifestations of two unrelated adult-
onset KD patients
A 12-year-old male (KD1) has been suffering slow 
progressive spastic gait disturbance since three months 
ago. He had one younger brother and their parents were 
non-consanguineous. In the family history, his maternal 
grandfather (I-3) died at age 40 from an unknown cause 
of cardiac arrest, but other family members including his 
parents (II-5 and 6) and brother (III-2) remained healthy 
at the time of this analysis (Figure 1A, left). Neurological 
examination of the patient revealed mild spastic 
weakness on lower extremities, exaggerated patellar 
tendon reflexes, and positive Babinski reflex and ankle 
clonus. Postural tremors with mild dysmetria in finger-
to-nose test were also noted in his upper limbs. While 
there was no detectable defect in general developmental 
state, sensory function, and autonomic function, the 
patient showed abnormal phonemic generative naming 
ability (below 1% of age group) in comprehensive 
neuropsychological tests, suggesting frontal dysfunction. 
Laboratory studies of biochemical and cerebrospinal 
fluid screening indicated that plasma electrolytes, liver 
function, calcium, phosphate, thyroid function, full 
blood count, vitamin B-12 and folate, syphilis serology, 
and autoantibody profile, were all unremarkable. Highly 
specialized laboratory analyses further excluded some rare 
metabolic disorders and the level of very long chain fatty 
acids (VLCFA) level remained in a normal range. The 
enzymatic activity of hexosaminidase A and arylsulfatase 
A were also within the reference range. Importantly, the 
GALC enzymatic activity detected by LC-MS/MS in 
leukocytes was markedly decreased (1.8 nmol/hr/mg 
protein), in comparison to the activity that reached 137.5 
nmol/hr/mg protein in an age-matched control (Table 1).
Direct sequencing of the GALC gene (Reference 
mRNA sequence: NM_000153.3) in this KD1 patient 
identified a novel nonsense mutation (c.1687A>T:p.
K563*) in exon 15 in combination with a known missense 
mutation (c.1901T>C:p.L634S) in exon 16 (Figure 1B, 
left). Because his parents did not show any abnormal 
phenotype, we suggest that such compound heterozygous 
mutations are likely responsible for various disease 
phenotype in the patient. Brain MR images further 
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revealed high-intensity lesions in the precentral motor 
cortex, corona radiata, posterior limb of the internal 
capsule, cerebral peduncle of the bilateral pyramidal tracts 
and optic radiation, with sparing of the periventricular 
white matter in fluid attenuated inversion recovery 
(FLAIR) and T2-weighted images (Figure 1C). Visual 
evoked potentials showed prolonged P100 latency in both 
eyes and prolonged central motor conduction times were 
observed in transcranial motor-evoked potentials.
We recently identified another adult-onset KD 
patient. This 38-year-old female (KD2) was the eldest 
daughter of healthy non-consanguineous parents. She was 
born at full term by spontaneous vaginal delivery and the 
perinatal history was unremarkable. At the age of 30, she 
started to complain progressive gait difficulty and spastic 
gait disturbance. The family members including her 
parents (I-1 and 2) and her younger brothers and sisters 
(II-3, 4, 5, and 6) remained healthy at the time of this 
analysis (Figure 1A, right). Neurological examination at 
the age of 38 revealed mild spastic weakness on lower 
extremities, exaggerated bilateral patellar tendon reflexes, 
ankle clonus and positive Babinski sign. She was able to 
walk independently harboring postural instability. Postural 
tremors with mild dysmetria in finger-to-nose test were 
also noted in her upper limbs. 
The laboratory studies of biochemical and 
cerebrospinal fluid screenings showed normal activities. 
The level of very long chain fatty acids (VLCFA) level, 
and the enzymatic activity of hexosaminidase A and 
arylsulfatase A were within the reference range. The 
GALC enzymatic activity detected by LC-MS/MS in 
leukocytes was evidently decreased (5.1 nmol/hr/mg 
protein) compared to 72.9 nmol/hr/mg protein in an age-
matched control. We also performed capillary sequencing 
of the GALC gene in this KD2 patient and identified the 
compound heterozygous mutations including c.857G>A 
(p.G286D) in exon 8, and c.683_694delinsCTC (p.N228_
S232delinsTP) in exon 7 (Figure 1B, right). Brain MRI 
revealed high-intensity signal in the precentral gyrus and 
posterior limb of the internal capsule, but showed no signal 
abnormality on the T1-weighted and contrast-enhanced 
T1-weighted images (Figure 1C). Visual evoked potentials 
were prolonged P100 latency in both eyes. These features 
suggest that KD2 has a similar array of clinical symptoms 
to KD1, despite the fact they carry distinct mutations in 
their GALC genes.
Subcellular localization of mutant GALC proteins 
in transfected cells and characterization of 
cultured skin fibroblasts from KD patients
In order to examine subcellular localization of 
GALC, we overexpressed the cDNA encoding wild-
type or mutant GALC C-terminally tagged with FLAG 
or HA in HeLa cells. In cells expressing either FLAG-
tagged wild-type, p.L634S, p.G286D, or HA-tagged 
p.K563*, p.N228_S232delinsTP GALC construct, all 
exogenous proteins were predominantly co-localized 
with the endoplasmic reticulum (ER) marker (Calnexin), 
but not with the lysosomal marker lysosomal-associated 
membrane proteins 1 (LAMP1) (Supplementary Figure 1). 
Therefore, the cellular localization of each overexpressed 
mutant GALC protein was indistinguishable from that of 
the wild-type enzyme.
Patient-derived skin fibroblasts were previously 
Table 1: Patients and controls whose skin fibroblasts were studied
Characteristic KD1 KD2 CTL1 CTL2 CTL3
Sex M F F F M
GALC genotype c.[1687A<T];[1901T>C]p.[K563*];[L634S]
c.[683_694delinsCTC];[857G>A]
p.[N228_S232delinsTP];[G286D] N/A N/A N/A
Phenotype Adult onset Adult onset Asymptomatic Asymptomatic Asymptomatic
Age at onset, yr 12 30 N/A N/A N/A
Age at biopsy, yr 12 38 15 35 58
Enzyme activity (nmol/
hr/mg protein) a 1.8 5.1 N/A N/A N/A
Enzyme activity indicates β-galactosylceramidase activity in lymphocytes.
CTL = control; F = Female; KD = Krabbe disease; M = male; N/A = not applicable
a Healthy control enzyme activity = 50-150 nmol/hr/mg protein.
Oncotarget74499www.impactjournals.com/oncotarget
used to characterize other lysosomal storage diseases, such 
as Niemann Pick type C or mucolipidosis type VI, both 
showing enlarged lysosomes [12]. To determine whether 
such morphological changes in lysosome were also related 
to diminished GALC activity in KD leukocytes, we 
cultured fibroblasts from healthy controls (CTL1, CTL2, 
CTL3) and two KD patients KD1 and KD2. Confocal 
imaging of both lysosomal-associated membrane protein 
Figure 1: Identification of the disease-causing mutations of GALC in two unrelated families. A. Pedigrees of two KD 
patients (left: KD1; right: KD2) with GALC mutations. The available DNA samples are indicated by asterisks (*). The probands are marked 
with arrows with filled symbols. Hashed symbols indicate deceased individuals. B. Sanger sequencing of the GALC gene (Reference mRNA 
sequence: NM_000153.3) from the patients identified c.1901T>C (p.L634S) combined with c.1687A>T (p.K563*) (left) and c.857G>A 
(p.G286D) combined with c.683_694delinsCTC (p.N228_S232delinsTP) (right). C. Brain MR images of KD1 patient revealed the severe 
high intensity signal of the precentral gyrus, corona radiata, posterior limb of internal capsule, cerebral peduncle of the bilateral pyramidal 
tracts and optic radiation on fluid-attenuated inversion recovery (FLAIR) and T2-weighted images. Brain MRI of the patient KD2 revealed 
the high intensity signal in the precentral gyrus and posterior limb of internal capsule, without signal abnormality on the T1-weighted and 
gadolinium-enhanced T1-weighted images.
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1 and 2 (LAMP1 and LAMP2) revealed increased LAMP1 
and LAMP2-positive vesicles in both patient fibroblasts, 
compared to all healthy controls (Figure 2A). In order 
to determine potentially altered lysosomal morphology 
in the patient fibroblasts, we imaged the lysosomal 
membrane using super-resolution stimulated emission 
depletion (STED) microscopy. STED imaging of both 
patient fibroblasts revealed markedly enlarged polygonal 
lysosome structures of various sizes, while control 
fibroblast showed uniformed spherical puncta shaped 
lysosomes (Figure 2B). Alterations in vesicle size in the 
patient cells were further confirmed by comparing vesicle 
diameters between healthy controls and the patients 
(Figure 2C-2E). Together, these data suggest that lysosome 
enlargement and increased expression of LAMP1 and 2, 
both common features in other lysosomal storage diseases, 
were also observed in KD patient-derived fibroblasts.
KD iNeurons directly converted from the patient 
skin fibroblasts demonstrates reduced GALC 
activity and accumulated of psychosine
Recent reports showed the association of myelin-
free neuronal and axonal defects with the KD pathology in 
the Twitcher model [7, 8]. We therefore trans-differentiated 
skin fibroblasts from the KD patients and healthy controls 
(CTL1, CTL2, CTL3) into induced neurons (iNeurons) by 
using a lentivirus that represses PTBP1, an RNA binding 
protein whose down-regulation has been demonstrated 
Figure 2: Immunofluorescent analysis of the fibroblast cultures from the KD patients. A. Control and both KD1 and KD2 
fibroblasts were fixed, permeabilized, and stained. LAMP1 (green) and LAMP2 (red) are both expressed higher in the patients compared to 
a representative healthy control fibroblasts. Enlarged images of the regions highlighted by dashed white squares in merged images (left) are 
in the right columns. DNA is identified by DAPI. Scale bars: 25 µm. B. Representative STED images of LAMP1 morphology differences 
in healthy controls and KD fibroblasts. LAMP1 morphologies are altered with enlarged and fragmented LAMP1-positive vesicles. Nuclei 
are indicated by asterisks (*). Scale bars: 5 µm. C.-E. The increased distribution ranges of lysosome diameters in patient fibroblasts (D, 
KD1: range, 0.74-4.15 µm; E, KD2: range, 0.75-4.68 µm) compared to healthy control fibroblasts (C, CTL: range, 0.36-1.03 µm). For each 
plot, n = 20 cells.
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to be necessary and sufficient to induce iNeurons from 
both murine and human fibroblasts [13, 14]. To promote 
iNeuron conversion, puromycin-resistant cells at 60 h 
post-infection, were replaced in N3 media containing 
the basic fibroblast growth factor (bFGF), supplemented 
with neurotrophic factors (Figure 3A). Within 1 day after 
infection, cells underwent morphological changes from flat 
spindle-shaped fibroblasts to spherical-shaped cell bodies 
with neurites (Figure 3B, 3C). The advanced maturated 
morphology of iNeurons with dendritic branching was 
confirmed by immunostaining with the neuronal dendrite 
marker MAP2 at day 8 of neuronal induction (Figure 3D). 
To test if compound heterozygous mutations in GALC 
affected the enzymatic activity in iNeurons, we measured 
the GALC activity from a representative control and both 
patient whole cell extracts using an enzymatic assay, 
as previously described [15]. GALC from both patient 
iNeurons showed significantly reduced GALC activity 
than that of controls (KD1 = ~67%; KD2 = ~51% of 
control iNeurons activity) (Figure 3E). MALDI-TOF 
mass spectrometry analysis of pure psychosine revealed 
ion peaks at m/z 445 ( [M-OH]+), 463 ( [M+H]+), and 
485 ( [M+Na]+) as expected in the previous study (Figure 
3F) [16]. In control iNeurons, we detected no distinctive 
intensity of those peaks for psychosine (Figure 3G). 
MALDI-TOF analysis of patient iNeurons also revealed a 
strong ion peak at m/z 445 and a slight peak at m/z 462 for 
KD1 iNeurons, indicating increased psychosine levels in 
the patient cells (Figure 3H). Similarly, a strong intensity 
of a peak was also detected at m/z 445 in KD2 iNeurons 
(Figure 3I). Taken together, these data demonstrated 
that both adult-onset KD patient-derived iNeurons show 
significantly reduced GALC enzymatic activity along 
with increased psychosine levels, despite the patients 
carry distinct sets of mutations in the GALC gene, thus 
providing ideal cellular models to link the genotypes to 
other potential disease phenotypes.
Figure 3: GALC enzymatic activity and MALDI-TOF mass spectrometry of iNeurons from KD patients. A. Schematic 
representation of the conversion process from human fibroblasts to iNeurons in response to PTBP1 shRNA. Within one day of neuronal 
induction, cells underwent morphological changes from flat fibroblastic spindle-shaped cells B. to distinctive round cell bodies with neurites 
C. (B, C = 200×). D. Immunofluorescence of cultures at day 8 reveals iNeurons expressing neuronal markers, MAP2 (green, neuronal 
dendrite marker) and TUJ1 (red, the early neuronal marker βIII-tubulin). DNA is identified by DAPI. Scale bars: 100 µm. E. GALC activity 
toward MUGal substrate (nmols/hr) measured from 15 µg of whole-cell protein extracts from a representative healthy control and KD 
iNeurons. Activity is presented as means ± SEM, n = 4. One-way ANOVA followed by Tukey multiple comparisons test; *p < 0.001. F. The 
psychosine standard substance of the [M-OH]+ signal at mass/charge (m/z) 445, [M+H]+ at m/z 463, and [M+Na]+ at m/z 485 are analyzed 
by positive ion mode MALDI-TOF mass spectrometry. Compared to control iNeurons G., distinctive molecular ion peaks [M-OH]+ at m/z 
445 and [M+H]+ at m/z 462 could be detected in KD1 iNeurons H.. I. Strong peak of [M-OH]+ was also obtained in KD2 iNeurons. 
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KD iNeurons demonstrate impaired lysosome 
morphology and accumulation
By both immunostaining and immunoblot analysis, 
we first characterized distinctive disease phenotypes 
on iNeurons. We found that the level of LAMP1 was 
increased in KD iNeurons, which was well coincided 
with the results obtained by the fibroblast modeling test 
(Figure 4A, 4B). To determine whether the morphology 
of lysosomal membrane was also altered in patient 
iNeurons, as in patient fibroblasts, we imaged the 
lysosomal membrane using STED microscopy. Indeed, 
STED imaging of patient iNeurons revealed that LAMP1-
positive vesicles were enlarged and irregularly shaped 
compared to control iNeurons (Figure 4C). Alterations in 
vesicle size in patient iNeurons were further confirmed by 
comparing vesicle diameter ranges between control and 
patient iNeurons (Figure 4D-4F). Therefore, lysosomal 
impairment remained similarly manifested after converting 
patient fibroblasts to iNeurons.
KD iNeurons reveal axonal defects
Axonal defects appear to directly contribute to the 
Twitcher pathogenesis in the murine model. Pathological 
axon swellings and early axonal loss have been shown 
to precede demyelination in isolated mutant neurons, 
thus suggesting an autonomous neuronal damage in the 
Twitcher mutants [7, 8]. To explore if genetic defects 
in KD patients affect neuronal or axonal pathology, we 
assessed myelin-independent neurite outgrowth and 
axonopathy on KD iNeurons in comparison with healthy 
controls. In line with previous studies on the Twitcher 
mouse model, iNeurons stained with TUJ1, MAP2, 
synapsin (neuronal marker), and vesicular glutamate 
transporter 1 (vGLUT1; glutamatergic neuronal marker) 
revealed that KD iNeurons, after culturing for 10 days 
in vitro, had rounded cell body with neurites shorter 
than those found in control iNeurons (Figure 5A-5C). In 
addition, we also noted the decreased number of neurites 
and axonal swellings in KD iNeurons compared to the 
Figure 4: LAMP1 vesicles accumulate in KD iNeurons. A. LAMP1 (green) expression is increased in patient iNeurons positive 
for TUJ1 (red). Enlarged images of the regions highlighted by dashed white squares in merged images (left) are in the right columns. DNA 
is identified by DAPI. Scale bars: 100 µm (enlarged images: 25 µm). B. Whole-cell protein extracts from a representative healthy control 
and patient iNeurons analyzed by immunoblotting show similar amount of GALC expression but the increase in LAMP1 was confirmed. 
GAPDH and TUJ1 are shown as loading controls (n = 4). C. Representative STED images of LAMP1 morphology differences in control 
and the two KD patient iNeurons. Alterations of LAMP1 morphologies are demonstrated with enlarged and irregularly shaped LAMP1-
positive vesicles in KD iNeurons. Nuclei are indicated by asterisks (*). Scale bars: 5 µm. D.-F. The increased distribution ranges of 
lysosome diameters in KD iNeurons (E, KD1: range, 0.79-4.64 µm; F, KD2: range, 0.63-4.3 µm) compared to control iNeurons (D, CTL: 
range, 0.25-0.99 µm)). For each plot, n = 15 cells.
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Figure 5: Defects of neuritic properties in KD iNeurons. A.-C. Ten days after neuronal induction, expression of mature neuronal 
markers show reduced neurite outgrowth in KD iNeurons (n = 5). Red: TUJ1; green: MAP2 A., Synapsin B., vGLUT1 C.; blue: DAPI. 
Scale bars: 50 µm. D.-E. At twenty days after neuronal induction, we visualized actin filaments by phalloidin staining to investigate the 
cytoskeletal organization of a representative healthy control and KD iNeurons. The phalloidin double-labeled with TUJ1 D. and TAU E. 
showed abnormal neuritic branching and defective axonal outgrowth in both patients compared to the healthy controls. The zoomed insets 
of highlighted regions are presented to the right of each image (n = 3). DNA is identified by DAPI. Scale bars: 50 µm (enlarged images: 
20 µm).
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healthy controls. In order to examine potential difference 
in cytoskeletal structure between controls and KD 
patient iNeurons, we stained the cells with fluorescent 
phalloidin for actin. The phalloidin double-labeled with 
early neuronal (Figure 5D) and axonal marker (Figure 5E) 
showed shorter and disorganized actin filaments with less 
neuritic branching and defective axonal outgrowth in both 
patients compared to controls. These data established a 
linkage of defective GALC to neuronal defects.
Psychosine treatment causes neuropathology in 
control iNeurons
During autophagy, autophagosome fuses with 
lysosome to degrade autophagy substrates. Because 
autophagic clearance of mitochondria is coordinated by 
lysosomes, aberrant lysosomes lead to mitochondrial 
dysfunctions, thus altering mitochondrial morphology 
[17, 18]. On the Twitcher model, both wild-type and 
mutant neurons exposed to psychosine showed defective 
mitochondrial transport, suggesting a causal cell 
autonomous effort of the metabolite [9]. To determine 
Figure 6: Psychosine induces lysosome accumulation, neurite and mitochondrial defects in control iNeurons. A. 
Representative healthy control and KD iNeurons were transfected with Mito-GFP to visualize mitochondria and incubated with Lysotracker-
Red to visualize lysosomes in live cells. The right panels represent zoomed images of the boxed areas on the left. Mito-GFP are distributed 
evenly throughout the dendrites in live control iNeurons, while those are swollen or accumulated in live KD iNeurons (arrows) (n = 
7). Scale bars: 25 µm (zoomed images: 15 µm). B. Reduced moving speeds of mitochondria in patient iNeurons were measured using 
kymograph analysis. Moving speed is presented as means ± SEM, n = 80. One-way ANOVA followed by Tukey multiple comparisons 
test; *p < 0.05, **p < 0.001. C. JC-1 staining on live iNeurons from a representative control and the patients. Figure D. represents zoomed 
images of the boxed areas in C.. Control iNeurons have red fluorescence, sign of preserved mitochondrial membrane potential, whereas 
KD1 cells displayed strong green fluorescence and KD2 with weaker green fluorescence, sign of mitochondrial membrane depolarization 
(n = 5). Scale bars: 100 µm C., 15 µm D.. E. Images of live control iNeurons expressing Mito-GFP after 5 µM of psychosine treatment. 
Representative frames from time-lapse image series (0-3 h) are shown. Neurites are abolished and mitochondria are accumulated (arrows). 
The right panel is merged pictures of DIC and fluorescence images. Scale bars: 25 µm. F. Immunoblotting detection of LAMP1 and TUJ1 
neuronal marker confirmed that psychosine accumulation in healthy control iNeurons triggers lysosomal accumulation in a dose-dependent 
manner. LAMP1 of endogenous KD iNeurons is also presented.
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whether lysosomal alteration in KD patients also result in 
mitochondrial dysfunction, we compared mitochondrial 
morphology from KD patient-derived and control 
iNeurons by transfecting Mitochondria-targeted GFP 
(Mito-GFP) to label and observe mitochondria and by 
incubating with Lysotracker-Red to visualize lysosomes 
in live cells. Compared to control iNeurons, we found that 
both KD iNeurons clearly contained swollen, fragmented, 
or aggregated mitochondria (Figure 6A). Time-lapse 
movies recorded on the disease iNeurons demonstrated the 
induced morphological changes (Supplemental Movie 1). 
To analyze mitochondrial speed in iNeurons, we generated 
kymographs from these time-lapse movies using the 
kymograph plug-in of the ImageJ software. Reduction in 
the mean velocity of mitochondria was confirmed in both 
patient iNeurons (Figure 6B). 
We also evaluated the mitochondrial membrane 
potential by using membrane-permeant dye 
tetraethlbenzimidzolylcarbocyanine iodide (JC-1). 
Cells with high mitochondrial membrane potential 
forms aggregate yielding red fluorescent whereas cells 
with low membrane potential forms monomeric form 
of JC1 yielding a diffuse green fluorescence. When we 
treated control iNeurons with valinomycin to induce 
mitochondrial matrix dissipation, the cells displayed 
green fluorescent signals, thus validating the assay (data 
not shown). We next loaded cultured iNeurons with 
JC-1 for 20 min and proceeded to live cell imaging. As 
shown in Figure 6C and 6D, the iNeurons derived from 
controls showed a strong red fluorescence without green 
fluorescence, while we observed a clear green fluorescence 
in KD1 and weaker green fluorescence in KD2 patient 
iNeurons indicative of impaired mitochondrial membrane 
potential in both patient iNeurons with a greater extent in 
iNeurons derived from the KD1 patient. 
As GALC is responsible for catalyzing 
galactosylceramide (GalCer) and psychosine, defective 
GALC activity is expected to lead to the accumulation of 
psychosine to toxic levels, which has been demonstrated 
to be the cause for cell death in the Twitcher mouse 
model [19]. To determine whether psychosine is the 
cause for neuronal and axonal defects as shown in Figure 
5 and mitochondrial defects characterized in Figure 6A-
6D, we applied psychosine to Mito-GFP transfected 
control iNeurons. After 3 h of psychosine treatment, an 
increase in psychosine level caused both neurite defects 
and mitochondrial aggregation and swelling, thus 
recapitulating the typical phenotype observed in KD 
iNeurons (Figure 6E). To confirm the potential role of 
psychosine in causing neuronal death, we treated control 
iNeurons with different concentrations of psychosine. In 
a psychosine concentration-dependent fashion, control 
iNeurons demonstrated increased expression levels 
of LAMP1 as observed in KD iNeurons (Figure 6F). 
Together, these data demonstrated that KD iNeurons 
faithfully reflect the pathophysiology of KD patients, 
and more importantly, support the emerging hypothesis 
that psychosine accumulation in neurons triggers 
neuronal degeneration, which is likely a key event in the 
development of KD pathophysiology [7, 8, 20].
DISCUSSION
ß-Galactosylceramidase (GALC) deficiency in 
Krabbe disease (KD) patients leads to the accumulation 
of its substrates galactosylceramide (GalCer) and 
psychosine [19, 21]. Since these defects have not been 
characterized on any cellular model of KD patients, we 
generated induced Neurons (iNeurons) from human skin 
fibroblasts from two adult-onset KD patients carrying 
heterozygous mutations in the GALC gene. One KD 
patient (KD1) carries one novel and one known mutation 
(p.[K563*];[L634S]) in its genome and the other KD 
patient (KD2) contains two known mutations but in a 
novel combination p.[N228_S232delinsTP];[G286D]. In 
order to establish iNeurons, we first confirmed a set of 
known disease pathologies in KD patient fibroblasts. The 
amount of lysosomes was increased and the morphology 
of lysosomes was altered with enlarged vesicles.
Importantly, recent studies on the Twitcher mouse 
model raised a new disease paradigm, suggesting an urgent 
need for understanding pathophysiological mechanisms 
of GALC mutations directly on relevant human models. 
Hence, we directly converted iNeurons from patient 
fibroblasts to demonstrate the molecular defects that 
became manifested only in KD iNeurons. Our study 
takes full advantage of an efficient trans-differentiation 
system, which does not involve intermediate pluripotent 
stem cells (iPSCs), to study such aspects in neuronal 
pathology associated with neurodegenerative diseases. 
The trans-differentiated cells demonstrated reduced GALC 
enzymatic activity, increased psychosine levels, axonal 
swelling and neurite defects in KD iNeurons, which are 
similar to the defects seen in the reported autopsy cases 
and in the Twitcher mouse model [7, 22]. 
In addition, we also detected morphological 
alterations in lysosomes and their accumulation in KD 
iNeurons. To elucidate whether the lysosomal alteration 
in KD patient iNeurons resulted in mitochondrial defects, 
we compared the morphology of mitochondria of live 
iNeurons derived from healthy controls and KD patients 
and observed irregularly shaped mitochondria and their 
fragmentation and aggregation in KD iNeurons. Since 
aberrant psychosine accumulation has been described as 
a cause of KD, we treated healthy control iNeurons with 
this metabolite and demonstrated the psychosine toxicity 
in a concentration-dependent manner as observed in 
KD iNeurons. Similarly, we recapitulated mitochondrial 
phenotypic defects in psychosine-treated control 
fibroblasts, supporting that lysosomal alterations result in 
mitochondrial defects [17]. Therefore, based on the results 
shown in this study, we conclude that, while fibroblasts 
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may be a robust and feasible cell model, fibroblast-derived 
iNeurons are better for delineating KD pathologies.
As analysis of GALC genotypes could be easily 
performed on patient samples, previous studies on KD 
significantly correlated GALC genotypes with the KD 
disease phenotype. However, the correlation between 
mutant GALC activity and clinical severity has remained to 
be further substantiated, because deficient GALC activity 
in leukocytes apparently does not distinctly identify the 
clinical phenotypic characteristics [3, 4]. Distribution of 
a common mutation in adult-onset KD, GALC (p.L634S), 
for example, has been reported to be susceptible to a late-
onset, mild form of KD [23]. However, the patients with 
the p.L634S mutation combined with other mutations or 
with the homozygous p.L634S mutation in the GALC gene 
exhibited a broad range of GALC activities, indicating 
that lower enzymatic activity does not always track 
the clinical severity [2-4]. Moreover, another common 
mutation in adult-onset KD GALC (p.G286D) exhibits 
a broad range of GALC activities when combined with 
another mutation or with the homozygous p.G286D 
mutation [4, 24], again indicating a limited correlation 
between the loss of enzymatic activity and clinical 
severity. Interestingly, GALC (p.G286D) was reported to 
directly cause slow progressive late-onset KD, whereas 
GALC (p. N228_S232delinsTP) was documented to be 
responsible for infantile-onset KD [2, 25, 26]. However, 
when the two mutations were combined in KD2 patient, 
the patient showed slow progression of the disease, which 
suggests limitations in studies identifying the disease 
exclusively based on the genotype and enzymatic activity 
measurements. To accurately link the loss of enzymatic 
activity and clinical severity, patient-specific disease 
modeling is clearly needed to elucidate the genotype-
phenotype correlation. In this aspect, our current study 
suggests that patient-specific iNeurons carrying mutations 
in the GALC gene may serve as good cell models 
to recapitulate unique features of molecular defects 
associated with KD.
Recently, psychosine accumulation was shown 
to exist not only in myelinating glia, but also in KD 
neurons, suggesting the involvement of a myelin-
independent neuronal pathogenesis [8, 9]. For modeling 
KD pathology, previous research relied on animal models 
to investigate the molecular mechanisms underlying KD 
pathogenesis. The Twitcher mouse carries a naturally 
occurring premature termination codon (p.W399*) in the 
GALC gene, resulting in a complete loss of the GALC 
enzymatic activity. Accordingly, this authentic model of 
KD is in keeping with the pathology observed in human 
infantile-onset KD, suggesting the pathological basis for 
KD in humans and offering a model for testing potential 
therapies against the disease, such as hematopoietic stem 
cell transplantation or enzyme replacement therapy [27]. 
Although the model has been used currently for defining 
pathogenesis, the Twitcher mouse model does appear to be 
fully adequate for studying the KD mechanism because the 
naturally occurring mutation in both alleles in Galc in the 
Twitcher mouse has never been found in KD patients. In 
this study, we present the first study towards understanding 
the KD pathology on a human iNeuron model and showed 
the direct link of KD to autonomous neuropathy. Using 
such patient-derived iNeurons, we not only found the 
accumulation of lysosomes, but also lysosomal and 
mitochondrial morphological defects. Intriguingly, treating 
control iNeuron with psychosine disrupted morphologies 
of both lysosomes and mitochondria and increased their 
aggregation in a concentration-dependent manner. These 
findings provide key evidence for the hypothesis that 
psychosine toxicity underlies neuronal dysfunction in KD 
patients [7]. 
In conclusion, this study explores human iNeurons 
as patient-specific cell models. Addressing the obscure 
correlation between GALC enzymatic activity and 
clinical phenotype due to the lack of an adequate disease 
model, we investigated neuropathology in KD patients by 
generating patient-specific iNeurons. Our findings report 
the defects in organelles and GALC substrates, resulting 
in autonomous neuronal KD pathology. Psychosine 
treatment of healthy control iNeurons confirmed the 
psychosine toxicity hypothesis. This experimental 
strategy is applicable to GALC genotypes associated with 
both infantile-onset and adult-onset KD. Moreover, the 
rapidly converted iNeurons from KD patient will enhance 
mechanistic studies of the disease and development of 
various treatment options on patient-specific iNeurons will 
expedite the development of effective therapeutics against 
KD.
MATERIALS AND METHODS
Genomic DNA analysis
The study protocol was approved by the Institutional 
Review Board of Hanyang University Hospital (IRB# 
2011-R-63). Both patients and their family members were 
given written informed consent for direct sequencing of 
the GALC gene. Their genomic DNA were prepared from 
peripheral blood leukocytes using a Wizard Genomic 
DNA Purification kit (Promega). All 17 coding exons and 
flanking intronic regions of the GALC gene were amplified 
by polymerase chain reaction (PCR) using a set of specific 
primers. Direct sequencing was carried out using a 
BigDye Terminator Cycle Sequencing Ready Reaction kit 
(Applied Biosystems) on an ABI3100 Genetic Analyzer 
(Applied Biosystems). The characteristics of the KD and 
non-KD individuals whose samples were utilized for this 
study are summarized in Table 1.
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Cell cultures and conversion of human skin 
fibroblasts to iNeurons
HeLa cells were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10 % 
fetal bovine serum (Gibco), sodium bicarbonate, sodium 
pyruvate (Sigma-Aldrich), and antibiotics. For transfection 
of HeLa cells, the cDNA encoding wild-type human 
GALC C-terminally tagged with FLAG was cloned into 
the pcDNA3.1 vector (invitrogen). Four GALC mutations 
(p.L634S, p.K563*, p.G286D, p.N228_S232delinsTP) 
with either FLAG or HA tags were introduced by 
PCR-based mutagenesis. The cells were transiently 
transfected with each wild-type or mutant constructs 
using Lipofectamine 2000 (Invitrogen) according to 
the manufacturer’s instructions. The cells at 48 h post-
transfection were fixed for immunostaining.
Fibroblasts were obtained from forearm skin with 
punch biopsy. Fibroblasts were cultured and maintained in 
DMEM supplemented with 20% FBS, non-essential amino 
acids (all from Gibco), sodium bicarbonate (Sigma), and 
1% (vol/vol) Penicillin/Streptomycin/Fungizone (Cellgro). 
In all experiments, passage-matched fibroblasts (passages 
3-5) were used. Fibroblasts were seeded at a density 
of 1×104 cells/cm2 and used for experiments after cell 
synchronization by serum starvation at matched time 
points. 
For direct conversion procedure, human fibroblasts 
were seeded onto matrigel (BD Biosciences)-coated 24-
well tissue culture dishes or cell culture flasks (Nunc). 
Human iNeurons were generated from fibroblasts using 
lentiviral transduction of specific shRNAs against human 
PTBP1 (Sigma MISSION) according to the protocol 
described by Lim et al. [14]. Briefly, after the shRNA 
treatment, the cells were selected with 1 μg/ml puromycin. 
Selected cells were replaced for 3 days in N3 media 
(DMEM/F12 (Gibco) supplemented with 25 μg/ml Insulin, 
50 μg/ml apo-transferrin, 20 nM progesterone, 100 nM 
putrescine, and 30 nM sodium selenite (all Sigma)), 10 
ng/ml bFGF (Gibco), supplemented with BDNF, CNTF, 
GDNF, and NT3 (all PeproTech) as previously described 
[13, 14]. From day 4 to the day of analysis, the cells were 
maintained in N3 media supplemented with 2% FBS.
Enzyme assays
Activity of β-galactosylceramidase in lymphocytes 
was determined by a high performance liquid 
chromatography tandem mass spectrometry LC-MS/MS, 
expressed as nmol/hr/mg protein. For enzymatic activity 
in iNeurons, 15 μg sonicated protein extract (50 μl) were 
mixed with 100 μl of 1.5 mM the fluorogenic substrate 
4-methylumbelliferyl-β-D-galactoside (MUGal) (Sigma) 
resuspended in 0.1/0.2 M citrate/phosphate buffer, pH 
4.0. Reactions were incubated 30 min at 37 °C and then 
stopped with 0.2 M Glycine/NaOH, pH 10.6. Fluorescence 
of liberated 4-methylumbelliferone was monitored by 
absorbance at λex 360 nm and λem 446 nm and calculated 
the activity from a standard 4-methylumbelliferone 
(Sigma) curve [15]. 
Mass spectrometry
For psychosine identification, lipid extractions from 
iNeurons were analyzed using a matrix-assisted laser 
desorption and ionization time-of-flight (MALDI-TOF) 
Axima Confidence™ spectrometer. For the lipid extraction 
from cells, 10 μl of lysates from iNeurons received 30 
μl methanol and proceeded to centrifugation after 1 hr 
of vigorous shaking. Extracted lipids were then mixed 
with an equal quantity of α-cyano-4-hydroxycinnamic 
acid (CHCA) matrix and 1 μl of that mixture was loaded 
into the spectrometer sample plate. The samples were 
allowed to dry and were analyzed by MALDI-TOF mass 
spectrometry in positive ion mode. Psychosine is identified 
and quantified by mass/charge (m/z) in relation to standard 
psychosine (Santa Cruz Biotechnology).
Immunostaining and confocal microscopy
Cells were washed with 1×PBS, fixed with 
4% paraformaldehyde (PFA) for 15 min at room 
temperature, washed three more times with PBS, and 
immunofluorescence staining was performed. Cells 
were permeabilized with 0.3% Triton X-100 for 10 min 
at room temperature, and blocked for 1 hr in 5% normal 
goat serum (Vector Labs) after washing with PBS three 
times. Cells were incubated with primary antibodies 
for 2 hrs at room temperature, washed three times with 
1×PBS, and detected with secondary antibodies for 1 hr 
at room temperature. For actin counterstaining, iNeurons 
were incubated with rhodamine-labelled phalloidin 
(Thermo Fisher Scientific, 1:400) for 20 min. After three 
additional washings with 1×PBS, nuclei were stained 
with DAPI. Coverslips were mounted on glass slides with 
Fluoromount-G (SouthernBiotech). Primary antibodies 
were mouse monoclonal antibodies against LAMP2 
(monoclonal, Abcam, 1:1000), calnexin (Thermo Fisher 
Scientific, 1:100), and rabbit polyclonal antibodies to 
LAMP1 (monoclonal, Cell Signaling Technology, 1:1000). 
For neuronal cell markers, mouse monoclonal antibody 
against β-tubulin III (TUJ1; monoclonal, Covance, 1:1000) 
and rabbit polyclonal antibody to MAP2 (polyclonal, Cell 
Signaling Technology, 1:100), Synapsin I (polyclonal, 
Chemicon, 1:200), vGLUT1 (polyclonal, Synaptic 
Systems, 1:1000), and Tau (polyclonal, Thermo Fisher 
Scientific, 1:300) were used. Secondary antibodies were 
Alexa Fluor 488-conjugated and/or tetramethylrhodamine 
B isothiocyanate (TRITC)-conjugated mouse or rabbit 
antibodies (Gibco), and STAR 440SX-conjugated rabbit 
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antibodies (Abberior) for stimulated emission depletion 
(STED) imaging. Images were acquired with a Leica TCS 
SP5 confocal microscope or using a Leica TCS SP8 STED 
microscope.
Live imaging
Cultured iNeurons were grown in imaging dishes 
(Chamber slide Lab-Tek II 4; Fisher). To visualize 
mitochondria, the cells were transfected with a Mito-
GFP plasmid two days before the analysis. To visualize 
the lysosomes in live cells, iNeurons were incubated 
with 250 nM Lysotracker-Red DND-99 dye (Invitrogen) 
in medium at 37 °C for 30 min. After washing twice 
with PBS the medium was replaced with fresh medium. 
Images were taken one frame every 3 sec, for 3 min. 
Detection of mitochondrial membrane potential changes 
in live iNeurons were performed using membrane-
permeant tetraethylbenzimidazolylcarbocyanine iodide 
(JC-1) staining kit (Sigma) according to manufacturer’s 
instruction. To measure the speed of mitochondria, 
kymographs were generated and analyzed using ImageJ 
(Multiple Kymograph plugin). For psychosine toxicity 
test, cells were treated with psychosine and then imaged 
for 3 h, 2 frames every 30 min. Live imaging was acquired 
using a DeltaVision fluorescence microscopy system 
(Applied Precision) installed at the Hanyang Center for 
Research Facilities, Seoul.
Western blot analysis
iNeurons were collected on day 15, washed with 
PBS, and lysed using a protein extraction solution 
(Intron Biotechnology) containing phosphate inhibitor 
(Calbiochem). Cell lysates were centrifuged and protein 
concentrations were determined. 15 µg of whole-cell 
protein extracts from each sample were separated by 
7.5% or 10% sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and transferred at 400 mA 
onto PVDF membranes (GE Healthcare). Membranes 
were blocked with 5% skim milk. The primary antibodies 
used were mouse monoclonal antibodies against TUJ1 
(monoclonal, Covance, 1:1000) and rabbit polyclonal 
antibodies against GALC (polyclonal, Santa Cruz 
Biotechnology, 1:500), LAMP1 (monoclonal, Cell 
Signaling Technology, 1:1000), and GAPDH (polyclonal, 
Santa Cruz Biotechnology, 1:500). Membranes were 
developed using the Enhanced Luminescence kit 
(GenDepot). For psychosine toxicity test, control iNeurons 
were treated with control vehicle (DMSO) or 1, 5 μM 
psychosine (Sigma) for up to 3 h.
Vesicle-size measurements
Confocal and STED images of fibroblasts or 
iNeurons were acquired after staining with anti-LAMP1 
and random sections from cells were selected for analysis. 
The vesicles with morphologies with circular in geometry 
were chosen for measurements. Regions of interest 
(ROIs) were drawn over images and were measured and 
documented for statistical analysis. Clustered lysosomes 
were not included in the size analysis. 
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